Literature DB >> 33511430

Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.

Kivilcim Eren Erdogan1, Marina Pacheco2,3, Marco Gambarotti2, Giovanna Magagnoli2, Marta Sbaraglia4, Tommaso Frisoni5, Alberto Righi6,7, Angelo Paolo Dei Tos4,8.   

Abstract

The aim of this study is to assess the usefulness of beta-catenin immunohistochemical expression in the differential diagnosis of osteoid-producing primary tumors of bone. Seventy cases of osteoid-producing tumors of bone (24 conventional osteosarcomas, 18 osteoblastomas, 13 osteoblastoma-like osteosarcomas, 10 chondroblastomas, and 5 chondroblastoma-like osteosarcomas) diagnosed at Istituto Ortopedico Rizzoli were reviewed and evaluated for the intensity, extension, and subcellular distribution of immunohistochemical expression of beta-catenin. A majority of cases (73%, 51 cases) exhibited cytoplasmic and/or membranous positivity in varied degrees of intensity and proportion of positive cells, in the absence of nuclear staining. Fifteen cases (21%) were completely negative, including two osteoblastomas, five chondroblastomas, three conventional osteosarcomas, four osteoblastoma-like osteosarcomas, and one chondroblastoma-like osteosarcoma. A minority of cases (6%) including three osteoblastoma-like osteosarcomas and one osteoblastoma showed focal nuclear beta-catenin positivity with or without concomitant cytoplasmic staining. In the current series, beta-catenin showed not to be useful in the differential diagnosis of osteoid-producing primary bone tumors.

Entities:  

Keywords:  Beta-catenin; Bone; Chondroblastoma; Immunohistochemistry; Osteoblastoma; Osteosarcoma

Year:  2021        PMID: 33511430     DOI: 10.1007/s00428-020-03004-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

Review 1.  The Wnt signaling pathway in development and disease.

Authors:  Catriona Y Logan; Roel Nusse
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

2.  Role of immunohistochemical cyclo-oxygenase-2 (COX-2) and osteocalcin in differentiating between osteoblastomas and osteosarcomas.

Authors:  Zeinab H El-Badawi; Eman M S Muhammad; Hassan H Noaman
Journal:  Malays J Pathol       Date:  2012-06       Impact factor: 0.656

3.  Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Authors:  Scott M Riester; Jorge Torres-Mora; Amel Dudakovic; Emily T Camilleri; Wei Wang; Fuhua Xu; Roman R Thaler; Jared M Evans; René Zwartbol; Inge H Briaire-de Bruijn; Avudaiappan Maran; Andrew L Folpe; Carrie Y Inwards; Peter S Rose; Thomas C Shives; Michael J Yaszemski; Franklin H Sim; David R Deyle; Annalise N Larson; Mario A Galindo; Arjen G H Cleven; Andre M Oliveira; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Andre J van Wijnen
Journal:  J Orthop Res       Date:  2016-06-28       Impact factor: 3.494

Review 4.  An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.

Authors:  Daniel Baumhoer; Fernanda Amary; Adrienne M Flanagan
Journal:  Genes Chromosomes Cancer       Date:  2018-12-24       Impact factor: 5.006

5.  Osteoblastoma-like osteosarcoma: high-grade or low-grade osteosarcoma?

Authors:  Marco Gambarotti; Angelo P Dei Tos; Daniel Vanel; Piero Picci; Dino Gibertoni; Michael J Klein; Alberto Righi
Journal:  Histopathology       Date:  2018-11-04       Impact factor: 5.087

6.  Osteoblastoma-like osteosarcoma. The Rizzoli Institute experience.

Authors:  F Bertoni; P Bacchini; D Donati; A Martini; P Picci; M Campanacci
Journal:  Mod Pathol       Date:  1993-11       Impact factor: 7.842

7.  β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma.

Authors:  Yang Wan; Wendi Zhao; Yan Jiang; Debao Liu; Gang Meng; Yongping Cai
Journal:  Hum Pathol       Date:  2014-03-13       Impact factor: 3.466

8.  Nuclear beta-catenin in mesenchymal tumors.

Authors:  Tony L Ng; Allen M Gown; Todd S Barry; Maggie C U Cheang; Andy K W Chan; Dmitry A Turbin; Forrest D Hsu; Robert B West; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

9.  Recurrent rearrangements of FOS and FOSB define osteoblastoma.

Authors:  Matthew W Fittall; William Mifsud; Nischalan Pillay; Hongtao Ye; Anna-Christina Strobl; Annelien Verfaillie; Jonas Demeulemeester; Lei Zhang; Fitim Berisha; Maxime Tarabichi; Matthew D Young; Elena Miranda; Patrick S Tarpey; Roberto Tirabosco; Fernanda Amary; Agamemnon E Grigoriadis; Michael R Stratton; Peter Van Loo; Cristina R Antonescu; Peter J Campbell; Adrienne M Flanagan; Sam Behjati
Journal:  Nat Commun       Date:  2018-06-01       Impact factor: 14.919

10.  Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway.

Authors:  Karolin H Nord; Jenny Nilsson; Elsa Arbajian; Fredrik Vult von Steyern; Otte Brosjö; Anne-Marie Cleton-Jansen; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.